Nuformix PLC Collaboration with SGSC (5743S)
26 June 2018 - 5:00PM
UK Regulatory
TIDMNFX
RNS Number : 5743S
Nuformix PLC
26 June 2018
Nuformix Plc
("Nuformix" or "the Company")
Collaboration with St George Street Capital
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, announces it has entered into an initial
collaboration with St George Street Capital ('SGSC').
Under the terms of the agreement SGSC and Nuformix will
collaborate to generate new IP to support near-term SGSC clinical
trials. If successful, SGSC and Nuformix will extend the
collaboration across further SGSC clinical programmes where
appropriate.
Dr Dan Gooding, CEO, Nuformix plc, said: "St George Street
Capital shares core objectives with Nuformix - those of rapidly
unlocking the therapeutic potential of various known drugs to
transform patient lives. The conclusion of this Agreement allows
Nuformix to consider new options which have the potential to in
build out its collaborative pipeline.
"Whilst focussing on making significant strides forward in its
lead programmes, collaborative programmes allow Nuformix to create
additional value with reduced risk. In this first collaborative
announcement, we're delighted to support St George Street Capital
from its inception as we both seek to address previously
underserved patient populations with innovative treatments."
Mike Johnson, Managing Director of SGS said: "I am delighted to
announce the progress we have made in such a short time - we will
work collaboratively with those organisations that apply bold new
thinking and lateral approaches to help get treatments as quickly
as possible to the people who need them. Nuformix is one of those
companies that we believe will be instrumental in helping us
accelerate treatments to patients"
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
Enquiries:
Nuformix Plc +44 (0) 1223
Dan Gooding, CEO 423667
Gable Communications Limited +44 (0) 20
John Bick / Justine James 7193 7463
About Nuformix plc
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
About St George Street Capital
Established in 2018, St George Street Capital is a new type of
charity, sourcing investment to fast-track clinical trials to get
new treatments as quickly as possible to the people that need them.
Thousands of treatments with powerful potential are currently
stalled in development, keeping patients suffering needlessly. Our
mission is to apply bold new thinking and lateral approaches to
unlock all this therapeutic potential and transform the lives of
patients and their families.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCQQLBLVQFEBBL
(END) Dow Jones Newswires
June 26, 2018 03:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024